JP2024537288A5 - - Google Patents

Info

Publication number
JP2024537288A5
JP2024537288A5 JP2024521807A JP2024521807A JP2024537288A5 JP 2024537288 A5 JP2024537288 A5 JP 2024537288A5 JP 2024521807 A JP2024521807 A JP 2024521807A JP 2024521807 A JP2024521807 A JP 2024521807A JP 2024537288 A5 JP2024537288 A5 JP 2024537288A5
Authority
JP
Japan
Prior art keywords
amount
cell
polypeptide construct
attracting
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024521807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537288A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/078638 external-priority patent/WO2023062188A1/en
Publication of JP2024537288A publication Critical patent/JP2024537288A/ja
Publication of JP2024537288A5 publication Critical patent/JP2024537288A5/ja
Pending legal-status Critical Current

Links

JP2024521807A 2021-10-15 2022-10-14 Cd19結合t細胞誘引抗体の皮下投与 Pending JP2024537288A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163256056P 2021-10-15 2021-10-15
US63/256,056 2021-10-15
US202163281992P 2021-11-22 2021-11-22
US63/281,992 2021-11-22
PCT/EP2022/078638 WO2023062188A1 (en) 2021-10-15 2022-10-14 Subcutaneous administration of cd19-binding t cell engaging antibodies

Publications (2)

Publication Number Publication Date
JP2024537288A JP2024537288A (ja) 2024-10-10
JP2024537288A5 true JP2024537288A5 (enExample) 2025-10-17

Family

ID=84360007

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024521807A Pending JP2024537288A (ja) 2021-10-15 2022-10-14 Cd19結合t細胞誘引抗体の皮下投与

Country Status (16)

Country Link
US (1) US20250282864A1 (enExample)
EP (1) EP4415829A1 (enExample)
JP (1) JP2024537288A (enExample)
KR (1) KR20240099263A (enExample)
AU (1) AU2022364154A1 (enExample)
CA (1) CA3235228A1 (enExample)
CL (1) CL2024001075A1 (enExample)
CO (1) CO2024006099A2 (enExample)
CR (1) CR20240206A (enExample)
IL (1) IL311714A (enExample)
JO (1) JOP20240080A1 (enExample)
MX (1) MX2024004617A (enExample)
PE (1) PE20241619A1 (enExample)
TW (1) TW202332695A (enExample)
UY (1) UY39983A (enExample)
WO (1) WO2023062188A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12698512B2 (en) 2023-11-06 2026-08-04 City Of Hope Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers
AU2025227506A1 (en) 2024-03-01 2026-08-13 Amgen Research (Munich) Gmbh Cd19-selective t cell engaging molecule for treating autoimmune diseases/ autoimmune conditions
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
JP5798036B2 (ja) 2008-11-07 2015-10-21 アムゲン リサーチ (ミュンヘン) ゲーエムベーハー 小児急性リンパ芽球性白血病の新規治療
HUE043326T2 (hu) 2008-11-07 2019-08-28 Amgen Res Munich Gmbh Akut limfoblasztos leukémia kezelése
WO2016036678A1 (en) * 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
RU2651776C2 (ru) * 2015-12-01 2018-04-23 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Биспецифические антитела против cd3*cd19

Similar Documents

Publication Publication Date Title
JP2025016606A5 (enExample)
AU761516B2 (en) Chimeric anti-CD20 antibody treatment of patients receiving BMT or PBSC transplants
JP7160533B2 (ja) 多発性骨髄腫(mm)の処置
JP2024540054A5 (enExample)
JP2024102205A5 (enExample)
AU2024354737A1 (en) Combination therapy for cancer treatment
JP2014114288A5 (enExample)
US20100172903A1 (en) Combination of an Anti-Ep-CAM Antibody with a Chemotherapeutic Agent
JP2009519257A5 (enExample)
JP2019031567A5 (enExample)
JP2016514132A5 (enExample)
CN120514847A (zh) 用于类风湿性关节炎治疗的组合物及使用该组合物的方法
JP2002544231A5 (enExample)
RU2014117510A (ru) Лечение ревматоидного артрита
JP2015500822A5 (enExample)
JP2019532970A5 (enExample)
JP2019521156A5 (enExample)
JP2024023347A5 (enExample)
JP2021523881A5 (enExample)
JP2021501800A5 (enExample)
EP0303687B1 (en) Compositions for enhancing adcc therapy
JP2023521853A5 (enExample)
JP2023500480A5 (enExample)
JP2023506779A5 (enExample)
JP2002530354A (ja) 移植の拒絶反応の出現の処置に使用するためのcd25結合分子